デフォルト表紙
市場調査レポート
商品コード
1081056

体外式膜型人工肺市場:現状分析と予測(2021年~2027年)

Extracorporeal Membrane Oxygenation Machine Market: Current Analysis and Forecast (2021-2027)

出版日: | 発行: UnivDatos Market Insights Pvt Ltd | ページ情報: 英文 248 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
体外式膜型人工肺市場:現状分析と予測(2021年~2027年)
出版日: 2022年05月01日
発行: UnivDatos Market Insights Pvt Ltd
ページ情報: 英文 248 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

体外式膜型人工肺の市場規模は、予測期間(2021年~2027年)に約5%のCAGRで拡大すると予測されています。さらに、WHOによると心臓血管手術の増加、冠動脈疾患(CAD)や心不全、重症急性呼吸窮迫症候群(ARDS)などの心臓・肺疾患の発生率の上昇は、今後数年間、体外式膜型人工肺市場を牽引すると予想されています。

当レポートでは、体外式膜型人工肺市場について調査し、市場の現状とともに、モダリティ別、用途別、コンポーネント別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクション

第2章 調査手法または仮定

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 体外式膜型人工肺(ECMO)市場におけるCOVID-19の影響

第6章 体外式膜型人工肺(ECMO)市場の収益(10億米ドル)、2019年~2027年

第7章 モダリティ別の市場洞察

  • VA(静脈→動脈)
  • VV(静脈→静脈)
  • AV(動脈→静脈)

第8章 用途別の市場洞察

  • 心臓
  • 呼吸器
  • 体外心肺蘇生法(ECPR)

第9章 コンポーネント別の市場洞察

  • ポンプ
  • 酸素供給器
  • コントローラー
  • カニューレ
  • 付属品

第10章 エンドユーザー別の市場の洞察

  • 病院、クリニック
  • 外来手術センター
  • その他

第11章 地域別の市場洞察

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第12章 体外式膜型人工肺(ECMO)の市場力学

  • 市場の促進要因
  • 市場の課題
  • 影響分析

第13章 体外式膜型人工肺(ECMO)市場の機会

第14章 体外式膜型人工肺(ECMO)市場の動向

第15章 法規制の枠組み

第16章 需要側と供給側分析

  • 需要側分析
  • 供給側分析

第17章 競合シナリオ

  • 競合情勢
    • ポーターのファイブフォース分析

第18章 企業概要

  • Fresenius Medical Care AG & Co. KGaA
  • Getinge Group
  • Medtronic plc
  • Terumo Cardiovascular Systems Corporation
  • Nipro Corporation
  • Xenios AG
  • Alung Technologies, Inc.
  • Livanova plc
  • Eurosets SRL
  • Abiomed

第19章 免責事項

目次
Product Code: UMHE21798

ECMO Machine Market is anticipated to display a CAGR of around 5% over the forecast period (2021-2027). Moreover, according to the World Health Organization The increase in the number of Cardiovascular surgeries, as well as the rising incidences of Heart and Lung diseases such as coronary artery diseases (CAD) and cardiac failure or severe acute respiratory distress syndrome (ARDS), are expected to drive the market for extracorporeal membrane oxygenation machine market in the coming years. according to WHO, Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Furthermore, around 17.9 million people died because of CVDs in 2019, and 85% of these deaths were due to Heart attack. In addition, the growing geriatric elderly population in developing countries coupled with the increase in the prevalence of chronic inflammatory lung diseases is further expected to create the demand the ECMO machine market. Moreover, the adoption of minimally invasive surgeries across geographies is another crucial factor driving the market.

Insights Presented in the Report

"Amongst modality, Arterial-venous segment held significant market share in 2020"

Based on the modality, the market bifurcated into veno-arterial, veno-venous, arterial-venous. Among these segments Arterial-venous (VA-ECMO) is projected to attain the largest market share in 2020 and expected to increase with a healthy CAGR in forecast period. The use of Arterial-venous (VA-ECMO) promotes gas exchange, especially the removal of carbon dioxide, by pumping blood into the circulatory system using the patient's arterial pressure.

Arterial-Venous provides removal of Carbon dioxide (ECCO2 R) from the body, by using patients own Arterial pressure to pump the blood. Furthermore, advantages linked with this segment area such as better medical evaluation, and effective dynamic range are contributing to its market expansion. Using ECMO machines, various steps are included in the treatment process, such as surgeries, post-operative follow-ups, and the current condition of the patient's heart & lungs. Thus, due to the rising demand for early diagnosis and effective treatment, is further contributing to the category's growth. ECMO's accuracy, and speed encourages its adoption, and it is expected to grow in popularity in the future.

"Amongst Application, Respiratory acquires largest market share"

Based on the application, the market is segmented into cardiac, respiratory, and extracorporeal cardiopulmonary resuscitation (ECPR). Of these three, chronic respiratory diseases acquired the largest share of the market in 2020. The growth of the segment is mainly due to the rising prevalence of chronic diseases, a number of cardiac surgeries entwined with the growing aging population around the world, which is further expected to fuel the growth of ECMO machines.

According to data published by the Extracorporeal Life Support Organization (ELSO), in 2015, over 2,600 patients in the U.S. with respiratory diseases received ECMO therapy. Moreover, ECMO has been used on 151,683 patients through 2020, including 30,743 children, 45,205 neonates, and 75,735 adults. Furthermore, rising alcohol consumption and smoking coupled with a sedentary lifestyle are growing the worldwide burden of cardiac and respiration illnesses in adults.

"Amongst End-User, Hospitals & Clinics acquires largest market share"

Based on end-user, the market is segmented into hospitals & clinics, ambulatory surgery centers, and others. Among these segments, ECMO machine market is in high demand in hospitals & Clinics because it provides advanced tools to orthopedic surgeons to improve visualization of complex cases, improve medical care efficiency, reduce time and healthcare costs, improve data management, and many other benefits. In addition to this, a rise in the number of healthcare facilities across countries coupled with the surging investment in the research and development by the hospitals are resulting in the growth of the extracorporeal membrane oxygenation machine market. Furthermore, the government across countries are investing in the healthcare industry for advancements and technological upgradation. Moreover, rising patient footfall in hospitals owing to ease of accessibility to the majority of healthcare services in one place is likely to boost the segment growth.

"North America will Dominate the Market During the Forecast Period"

For a better understanding of the market adoption of ECMO machines, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), and Rest of World. In 2020, the North American region held the highest market share in the global ECMO Machine market.

Some of the major players operating in the market are Fresenius Medical Care AG & Co. KGaA, Getinge Group, Medtronic plc, Terumo Cardiovascular Systems Corporation, Nipro Corporation, Xenios AG, Alung Technologies, Inc., Livanova plc, Eurosets S.R.L., Abiomed.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Customization Options:

The ECMO Machine Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Limitation
  • 1.3. Stakeholders
  • 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Extracorporeal Membrane Oxygenation (ECMO) Machine Market
  • 2.2. Research Methodology of the Extracorporeal Membrane Oxygenation (ECMO) Machine Market
  • 2.3. Forecasting Method
  • 2.4. Respondent Profile
  • 2.5. Main Objective of the Extracorporeal Membrane Oxygenation (ECMO) Machine Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) MACHINE MARKET COVID-19 IMPACT

6 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) MACHINE MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY MODALITY

  • 7.1. Veno-Arterial
  • 7.2. Veno-Venous
  • 7.3. Arterio-Venous

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Cardiac
  • 8.2. Respiratory
  • 8.3. Extracorporeal cardiopulmonary resuscitation (ECPR)

9 MARKET INSIGHTS BY COMPONENT

  • 9.1. Pumps
  • 9.2. Oxygenators
  • 9.3. Controllers
  • 9.4. Cannula
  • 9.5. Accessories

10 MARKET INSIGHTS BY END-USER

  • 10.1. Hospitals & Clinics
  • 10.2. Ambulatory Surgery centres
  • 10.3. Others

11 MARKET INSIGHTS BY REGION

  • 11.1. North America
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Rest of North America
  • 11.2. Europe
    • 11.2.1. Germany
    • 11.2.2. UK
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. Asia-Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Australia
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4. Rest of World

12 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) MACHINE SOFTWAREMARKET DYNAMICS

  • 12.1. Market Drivers
  • 12.2. Market Challenges
  • 12.3. Impact Analysis

13 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) MACHINE MARKET OPPORTUNITIES

14 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) MACHINE MARKET TRENDS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

  • 16.1. Demand Side Analysis
  • 16.2. Supply Side Analysis

17 COMPETITIVE SCENARIO

  • 17.1. Competitive Landscape
    • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

  • 18.1. Fresenius Medical Care AG & Co. KGaA
  • 18.2. Getinge Group
  • 18.3. Medtronic plc
  • 18.4. Terumo Cardiovascular Systems Corporation
  • 18.5. Nipro Corporation
  • 18.6. Xenios AG
  • 18.7. Alung Technologies, Inc.
  • 18.8. Livanova plc
  • 18.9. Eurosets S.R.L.
  • 18.10. Abiomed

19 DISCLAIMER